A phase i clinical trial of CD1c (BDCA-1)+ dendritic cells pulsed with HLA-A∗0201 peptides for immunotherapy of metastatic hormone refractory prostate cancer

Journal of Immunotherapy

Volumn 38, Issue 2, 2015, Pages 71-76

  Prue, Rebecca L ^a,e   Vari, Frank ^a   Radford, Kristen J ^a   Tong, Hui ^a   Hardy, Melinda Y ^a   D'Rozario, Rachael ^a   Waterhouse, Nigel J ^a,c   Rossetti, Tony ^a   Coleman, Robert ^a   Tracey, Christopher ^a   Goossen, Hans ^a   Gounder, Vinay ^a   Crosbie, Georgina ^a   Hancock, Sonia ^a   Diaz Guilas, Stephanie ^a   Mainwaring, Paul ^a,b   Swindle, Peter ^a,b   Hart, Derek N J ^a,d  

^a MATER MEDICAL RESEARCH INSTITUTE   (Australia)

^b Mater Private Hospital Brisbane   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d Department of Microbiology and Infectious Diseases   (Australia)

^e KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

cell therapy; clinical trial; dendritic cells; immunotherapy

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; CD1C ANTIGEN; DENDRITIC CELL VACCINE; HLA A ANTIGEN; KEYHOLE LIMPET HEMOCYANIN; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; ACID PHOSPHATASE; CANCER VACCINE; CD1 ANTIGEN; CD1C PROTEIN, HUMAN; GLYCOPROTEIN; HLA A2 ANTIGEN; HLA-A*02:01 ANTIGEN; PEPTIDE FRAGMENT;

ADULT; AGED; ANTIBODY RESPONSE; APHERESIS; ARTICLE; CANCER IMMUNOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; DENDRITIC CELL; DRUG EFFECT; DRUG FORMULATION; DRUG TOLERABILITY; FEVER; HEMATURIA; HUMAN; IMMUNE RESPONSE; INJECTION SITE REACTION; KIDNEY DISEASE; LIMB FRACTURE; MAJOR CLINICAL STUDY; MALE; NAUSEA; PAIN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; TACHYPNEA; THROMBOSIS; URETER STONE; ADOPTIVE IMMUNOTHERAPY; ANTIBODY SPECIFICITY; CANCER STAGING; CLINICAL TRIAL; FEASIBILITY STUDY; IMMUNOLOGY; INTRADERMAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; METASTASIS; MIDDLE AGED; MULTICENTER STUDY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TRANSPLANTATION;

ACID PHOSPHATASE; ADMINISTRATION, INTRAVENOUS; AGED; ANTIGENS, CD1; CANCER VACCINES; DENDRITIC CELLS; FEASIBILITY STUDIES; GLYCOPROTEINS; HLA-A2 ANTIGEN; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INJECTIONS, INTRADERMAL; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; ORGAN SPECIFICITY; PEPTIDE FRAGMENTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

EID: 84922759098     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000063     Document Type: Article

References (23)

1. Kassianos AJ, Jongbloed SL, Hart DN, et al. Isolation of human blood DC subtypes. Methods in Mol Biol. 2010;595:45-54.
2. Futterer JJ. Imaging of recurrent prostate cancer. Radiol Clin North Am. 2012;50:1075-1083.
3. Hammerer P, Madersbacher S. Landmarks in hormonal therapy for prostate cancer. BJU Int. 2012;110(Suppl 1):23-29.
4. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411-422.
5. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-1512.
6. Drakaki A, McDermott DF. Novel Immunotherapies in GU Malignancies. Curr Oncol Rep. 2013;15:224-231.
7. Drake CG. Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol. 2010;10:580-593.
8. Draube A, Klein-Gonzalez N, Mattheus S, et al. Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis. PLoS One. 2011;6:e18801.
9. Vulink A, Radford KJ, Melief C, et al. Dendritic cells in cancer immunotherapy. Adv Cancer Res. 2008;99:363-407.
10. Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009;115:3670-3679.
11. Small EJ, Schellhammer PF, Higano CS, et al. Placebocontrolled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006;24:3089-3094.
12. Kawalec P, Paszulewicz A, Holko P, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. A systematic review and meta-analysis. Arch Med Sci. 2012;8:767-775.
13. Sheikh NA, Petrylak D, Kantoff PW, et al. Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castrationresistant prostate cancer. Cancer Immunol Immunother. 2013;62:137-147.
14. Jefford M, Schnurr M, Toy T, et al. Functional comparison of DCs generated in vivo with Flt3 ligand or in vitro from blood monocytes: differential regulation of function by specific classes of physiologic stimuli. Blood. 2003;102:1753-1763.
15. Radford KJ, Turtle CJ, Kassianos AJ, et al. CD11c+ blood dendritic cells induce antigen-specific cytotoxic T lymphocytes with similar efficiency compared to monocyte-derived dendritic cells despite higher levels of MHC class I expression. J Immunother. 2006;29:596-605.
16. Luft T, Jefford M, Luetjens P, et al. Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E(2) regulates the migratory capacity of specific DC subsets. Blood. 2002;100:1362-1372.
17. Osugi Y, Vuckovic S, Hart DN. Myeloid blood CD11c(+) dendritic cells and monocyte-derived dendritic cells differ in their ability to stimulate T lymphocytes. Blood. 2002;100: 2858-2866.
18. Dzionek A, Fuchs A, Schmidt P, et al. BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J Immunol. 2000;165:6037-6046.
19. MacDonald KP, Munster DJ, Clark GJ, et al. Characterization of human blood dendritic cell subsets. Blood. 2002; 100:4512-4520.
20. Wilkinson R, Kassianos AJ, Swindle P, et al. Numerical and functional assessment of blood dendritic cells in prostate cancer patients. Prostate. 2006;66:180-192.
21. Tel J, Aarntzen EH, Baba T, et al. Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. Cancer Res. 2013;73:1063-1075.
22. Aarntzen EH, Srinivas M, Bonetto F, et al. Targeting of 111Inlabeled dendritic cell human vaccines improved by reducing number of cells. Clin Cancer Res. 2013;19:1525-1533.
23. Chen G, Emens LA. Chemoimmunotherapy: re-engineering tumor immunity. Cancer Immunol Immunother. 2013;62:203-216.